We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Evotec Enters License Agreement with Broad Institute

Rectangle Image
News

Evotec Enters License Agreement with Broad Institute

Read time:
 

Evotec AG has announced that it has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.

With this agreement, Evotec obtains non-exclusive access to the leading technology on the market for gene editing.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Alongside Evotec's comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company's continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline."

Advertisement